Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Radiol. Sep 28, 2024; 16(9): 482-488
Published online Sep 28, 2024. doi: 10.4329/wjr.v16.i9.482
Pneumocystis pneumonia in stage IIIA lung adenocarcinoma with immune-related acute kidney injury and thoracic radiotherapy: A case report
Ya-Wen Zheng, Jia-Chao Pan, Jin-Feng Wang, Jian Zhang
Ya-Wen Zheng, Jian Zhang, Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250000, Shandong Province, China
Jia-Chao Pan, Department of Gastroenterology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250000, Shandong Province, China
Jin-Feng Wang, Department of Pulmonary and Critical Care Medicine, Central Hospital Affiliated to Shandong First Medical University, Jinan 250000, Shandong Province, China
Co-corresponding authors: Ya-Wen Zheng and Jian Zhang.
Author contributions: Zheng YW and Zhang J conceived the manuscript; Zheng YW, Wang JF and Zhang J treated the patient; Zheng YW and Pan JC collected the patient information and acquired the data; Zheng YW and Pan JC analyzed the data and wrote the manuscript; Zheng YW and Zhang J jointly formulated the patient's treatment plan, with equal contributions to the manuscript as co-corresponding authors; Zheng YW takes primary responsibility for communication with the journal during the manuscript submission, peer review and publication processes; all authors reviewed the manuscript critically and approved the content.
Supported by Shandong Natural Science Foundation, No. ZR2021QH034; and China Postdoctoral Science Foundation, No. 2023M731305.
Informed consent statement: The authors certify that they have obtained all appropriate patient consent forms prior to study enrollment.
Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ya-Wen Zheng, MD, PhD, Associate Chief Physician, Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, No. 105 Jiefang Road, Jinan 250000, Shandong Province, China. zyawen06@126.com
Received: July 11, 2024
Revised: August 16, 2024
Accepted: September 3, 2024
Published online: September 28, 2024
Processing time: 77 Days and 16.7 Hours
Core Tip

Core Tip: A patient with squamous lung cancer was treated with triplimab combined with paclitaxel, carboplatin, and radical thoracic radiation therapy. Despite the good therapeutic effect, he developed a grade 3 immune-related acute kidney injury, prompting high-dose corticosteroids treatment. Eight weeks later, the patient developed severe pneumonia with spontaneous pneumothorax, and was diagnosed with Pneumocystis jirovecii pneumonia (PJP) co-infection with the herpes simplex virus 1 and cytomegalovirus. PJP is rare but might occur in patients with immune checkpoint inhibitor adverse events, highlighting the need to be differentiated from tumor progression or immune-related adverse events.